First subject enrolled in Bluejay Therapeutics’ trial of Hepatitis D treatment
Bluejay Therapeutics has enrolled the first subject in the randomised AZURE-2 global Phase III clinical trial to assess pan-genotypic, fully…
Gastrointestinal
-
-
First subject dosed in Resolution’s liver cirrhosis therapy trial
Resolution Therapeutics has dosed the first subject and cleared for safety in its multi-centre Phase I/II EMERALD trial, assessing RTX001,…
-
Vendanta’s culls UC microbiome therapy on Phase II fail
Vendanta Biosciences will be stopping development of its oral microbiome therapy, VE202, which failed to meet its primary endpoint in…
-
CuraCell gains German approval for clinical trial application of CC-38
CuraCell Holding’s clinical trial application (CTA) has received approval from Germany's federal authority for vaccines and biomedicines, Paul-Ehrlich-Institut (PEI), to…
-
Aligos commences dosing in Phase II trial for chronic hepatitis B treatment
Aligos Therapeutics has initiated dosing in the randomised Phase II B-SUPREME trial of its oral therapy, ALG-000184, in people with…
-
Palisade reports outcomes from Phase Ib ulcerative colitis study
Palisade Bio has reported positive outcomes from the Phase Ib open-label cohort of an ileocolonic-targeted PDE4 inhibitor, PALI-2108, in those…
-
FDA approves Anbogen’s ABT-301 trial for metastatic colorectal cancer
The US Food and Drug Administration (FDA) has approved Anbogen Therapeutics’ investigational new drug (IND) application for oral HDAC1/2/3 inhibitor…
-
Abivax stock surges 580% following dual Phase III success in UC
Abivax’s stock has soared by more than 500% after its first-in-class ulcerative colitis (UC) therapy impressed in a Phase III…
-
PDS Biotechnology completes recruitment for stage one of colorectal cancer trial
PDS Biotechnology has completed subject recruitment for stage one of its open-label Phase II trial, evaluating the systemic administration of…
-
Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint
Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with chemotherapy (mFOLFOX6), achieved…
